DUBLIN--(BUSINESS WIRE)--The 'Sickle Cell Disease Treatment Market by Treatment Type (Blood Transfusion, Bone Marrow Transplant, Pharmacotherapy), Patient Age Group (Adult, Pediatric), Drug Administration Method, Disease Type, End User - Global Forecast 2025-2030' report has been added to ResearchAndMarkets.com's offering..

都柏林--（商业新闻短讯）--“按治疗类型（输血、骨髓移植、药物治疗）、患者年龄组（成人、儿科）、药物管理方法、疾病类型、最终用户划分的镰状细胞病治疗市场——2025-2030年全球预测”报告已添加到ResearchAndMarkets.com的产品中。。

The Sickle Cell Disease Treatment Market grew from USD 2.85 billion in 2023 to USD 3.25 billion in 2024. It is expected to continue growing at a CAGR of 15.51%, reaching USD 7.84 billion by 2030.

镰状细胞病治疗市场从2023年的28.5亿美元增长到2024年的32.5亿美元。预计将继续以15.51%的复合年增长率增长，到2030年将达到78.4亿美元。

Key growth drivers include technological advancements in genetic research, a deeper understanding of disease pathophysiology, and governmental and non-governmental funding to enhance R&D initiatives. Emerging opportunities lie in developing gene therapy solutions and personalized medicine approaches, aimed at providing durable cures rather than symptomatic relief.

关键的增长驱动因素包括基因研究的技术进步，对疾病病理生理学的更深入了解，以及政府和非政府资助以增强研发计划。新兴的机会在于开发基因治疗解决方案和个性化医学方法，旨在提供持久的治疗而不是症状缓解。

Collaboration among pharmaceutical companies, healthcare providers, and research institutes is vital to translating these innovations into widely accessible treatments..

制药公司、医疗保健提供者和研究机构之间的合作对于将这些创新转化为广泛可用的治疗至关重要。。

Challenges include high treatment costs, limited awareness in certain demographics, and inadequate healthcare infrastructure in regions heavily affected by the disease. Intellectual property issues and regulatory barriers also hinder market growth. There is significant potential for innovation in CRISPR-Cas9 gene editing and developing novel drugs that increase fetal hemoglobin levels, which can ameliorate disease severity.

挑战包括高昂的治疗费用，某些人口统计数据的认识有限，以及受疾病严重影响地区的医疗保健基础设施不足。知识产权问题和监管障碍也阻碍了市场的增长。CRISPR-Cas9基因编辑和开发增加胎儿血红蛋白水平的新药具有巨大的创新潜力，可以改善疾病的严重程度。

Efforts in educational outreach can bridge gaps in patient understanding and compliance, enhancing treatment efficacy..

教育外展的努力可以弥合患者理解和依从性的差距，提高治疗效果。。

The market is characterized by dynamic competition and evolving regulatory frameworks, necessitating adaptive strategies for sustained success. Emphasizing patient-centric and cost-effective solutions while promoting collaboration and bridging inequalities in treatment access can drive substantial progress, positioning companies well in a market poised for growth amid challenges..

市场的特点是动态竞争和不断变化的监管框架，需要采取适应性策略才能持续成功。强调以患者为中心和具有成本效益的解决方案，同时促进合作和弥合治疗机会的不平等，可以推动取得实质性进展，使公司在面临挑战的市场中处于良好的增长状态。。

Market Drivers

市场驱动因素

Growing prevalence of sickle cell disease emphasizing the urgent need for effective therapeutic solutions

镰状细胞病的患病率越来越高，强调迫切需要有效的治疗方案

Rising awareness and education efforts about sickle cell disease stimulate demand for effective treatments

提高对镰状细胞病的认识和教育工作刺激了对有效治疗的需求

Government funding and initiatives encouraging research and development in sickle cell disease therapy

政府资助和鼓励镰状细胞病治疗研究和开发的举措

Market Restraints

市场约束

Lengthy and complex regulatory approvals delay the introduction of innovative treatments

冗长而复杂的监管批准延迟了创新疗法的引入

Market Opportunities

市场机会

Implementing telehealth services for routine check-ups and management support

为例行检查和管理支持实施远程保健服务

Integration of gene therapy developments to enhance long-term treatment outcomes for sickle cell disease

整合基因治疗发展以提高镰状细胞病的长期治疗效果

Market Challenges

市场挑战

Side effects and complications associated with sickle cell disease treatment

镰状细胞病治疗的副作用和并发症

Market Segmentation Analysis

市场细分分析

Treatment Type: Rising need for bone marrow transplants to replace the patient's defective bone marrow with healthy cells

治疗类型：对骨髓移植的需求不断增加，以健康细胞替代患者有缺陷的骨髓

End User: Increasing preference for hospitals due to their comprehensive care for sickle cell disease

最终用户：由于医院对镰状细胞病的全面护理，越来越偏爱医院

Recent Developments

最近的发展

Novo Nordisk pioneers sickle cell disease treatment in India

诺和诺德是印度镰状细胞病治疗的先驱

Novo Nordisk's strategic initiatives in India highlight the company's dual focus on addressing sickle cell disease and diabetes. The anticipated introduction of a sickle cell drug, currently in Phase-3 trials, aligns with India's goal to be sickle cell-free by 2045. This entails partnerships with state governments and academic institutions, aiming for better awareness, capacity building, and treatment..

诺和诺德在印度的战略举措突显了该公司对解决镰状细胞病和糖尿病的双重关注。目前正在进行第三阶段试验的镰状细胞药物的预期推出与印度到2045年实现无镰状细胞的目标相一致。这需要与州政府和学术机构建立伙伴关系，旨在提高认识、能力建设和治疗。。

Protagonist Therapeutics files for a patent aimed to treat sickle cell disease

Protation Therapeutics申请一项旨在治疗镰状细胞病的专利

Protagonist Therapeutics has filed a patent for a hepcidin mimetic to treat sickle cell disease, aiming to improve crucial blood parameters such as red blood cell counts and hemoglobin levels. Administered subcutaneously, the mimetic targets sickle cell anemia and related conditions.

Protation Therapeutics已经申请了一种用于治疗镰状细胞病的铁调素模拟物的专利，旨在改善关键的血液参数，如红细胞计数和血红蛋白水平。皮下给药，模拟物靶向镰状细胞性贫血和相关病症。

Casgevy and Lyfgenia gene therapies approved for sickle cell disease

Casgevy和Lyfgenia基因疗法被批准用于镰状细胞病

The approval of Casgevy and Lyfgenia as gene therapies marks a transformative shift in treating sickle cell disease (SCD), traditionally reliant on bone marrow transplants. These therapies employ gene-editing (Casgevy) and viral delivery (Lyfgenia) mechanisms to enhance hemoglobin production, potentially offering a lifelong cure..

Casgevy和Lyfgenia被批准作为基因疗法，标志着传统上依赖骨髓移植的镰状细胞病（SCD）治疗的变革性转变。这些疗法采用基因编辑（Casgevy）和病毒传递（Lyfgenia）机制来增强血红蛋白的产生，可能提供终身治疗。。

Key Company Profiles

主要公司简介

The report delves into recent significant developments in the Sickle Cell Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include Akums Drugs and Pharmaceuticals Ltd., Beam Therapeutics, Biogen, Bluebird Bio, Bristol-Myers Squibb Company, CRISPR Therapeutics, Editas Medicine, Emmaus Medical, F.

该报告深入研究了镰状细胞病治疗市场最近的重大发展，重点介绍了领先的供应商及其创新概况。其中包括Akums Drugs and Pharmaceuticals Ltd.，Beam Therapeutics，Biogen，Bluebird Bio，Bristol-Myers Squibb Company，CRISPR Therapeutics，Editas Medicine，Emmaus Medical，F。

Hoffmann-La Roche, GlycoMimetics, Intellia Therapeutics, Medunik USA, Novartis, Protagonist Therapeutics, Sangamo Therapeutics, Sanofi, Vertex Pharmaceuticals and Vor Biopharma..

霍夫曼·拉罗氏（Hoffmann-La Roche），糖模拟，Intellia Therapeutics，Medunik USA，诺华，Protation Therapeutics，Sangamo Therapeutics，赛诺菲，Vertex Pharmaceuticals和Vor Biopharma。。

Key Attributes:

关键属性：

Report Attribute

报表属性

Details

详细信息

Forecast Period

预测期

2023 - 2030

2023 - 2030

Estimated Market Value (USD) in 2023

2023年估计市值（美元）

$2.85 Billion

28.5亿美元

Forecasted Market Value (USD) by 2030

2030年预测市场价值（美元）

$7.84 Billion

78.4亿美元

Compound Annual Growth Rate

年均复合增长率

15.5%

15.5%

Regions Covered

覆盖的区域

Global

全球

Key Topics Covered:

涵盖的关键主题：

Sickle Cell Disease Treatment Market, by Treatment Type

Blood Transfusion

输血

Acute Transfusion

急性输血

Chronic Transfusion

慢性输血

Bone Marrow Transplant

骨髓移植

Allogeneic Transplant

同种异体移植

Autologous Transplant

自体干细胞移植

Pharmacotherapy

药物治疗

Endari (L-Glutamine) Treatment

Endari（L-谷氨酰胺）治疗

Gene Therapy

基因治疗

Hydroxyurea Treatment

羟基脲处理

Sickle Cell Disease Treatment Market, by Patient Age Group

镰状细胞病治疗市场，按患者年龄组

Adult

成人

Pediatric

儿科

Sickle Cell Disease Treatment Market, by Drug Administration Method

镰状细胞病治疗市场，按药物管理方法

Intravenous

静脉注射

Oral

口头

Sickle Cell Disease Treatment Market, by Disease Type

镰状细胞病治疗市场（按疾病类型）

Hemoglobin SC Disease (HbSC)

血红蛋白SC病（HbSC）

Sickle Cell Anemia (HbSS)

Sickle Cell Disease Treatment Market, by End User

镰状细胞病治疗市场（按最终用户）

Clinics

诊所

Hospitals

医院

Private Hospitals

私立医院

Public Hospitals

公立医院

Research Institutions

研究机构

Competitive Landscape

竞争格局

Market Share Analysis, 2023

2023年市场份额分析

FPNV Positioning Matrix, 2023

FPNV定位矩阵，2023年

Competitive Scenario Analysis

竞争情景分析

Novo Nordisk pioneers sickle cell disease treatment in India

诺和诺德是印度镰状细胞病治疗的先驱

Protagonist Therapeutics files for a patent aimed to treat sickle cell disease

Protation Therapeutics申请一项旨在治疗镰状细胞病的专利

Casgevy and Lyfgenia gene therapies approved for sickle cell disease

Casgevy和Lyfgenia基因疗法被批准用于镰状细胞病

Strategy Analysis & Recommendation

战略分析与建议

For more information about this report visit https://www.researchandmarkets.com/r/m5c3g1

有关此报告的更多信息，请访问https://www.researchandmarkets.com/r/m5c3g1

About ResearchAndMarkets.com

关于ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com是全球领先的国际市场研究报告和市场数据来源。我们为您提供有关国际和地区市场、关键行业、顶尖公司、新产品和最新趋势的最新数据。